204 related articles for article (PubMed ID: 23986513)
1. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.
Sullivan T; Miao Z; Dairaghi DJ; Krasinski A; Wang Y; Zhao BN; Baumgart T; Ertl LS; Pennell A; Seitz L; Powers J; Zhao R; Ungashe S; Wei Z; Boring L; Tsou CL; Charo I; Berahovich RD; Schall TJ; Jaen JC
Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1288-97. PubMed ID: 23986513
[TBL] [Abstract][Full Text] [Related]
2. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
[TBL] [Abstract][Full Text] [Related]
3. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice.
Kang YS; Lee MH; Song HK; Ko GJ; Kwon OS; Lim TK; Kim SH; Han SY; Han KH; Lee JE; Han JY; Kim HK; Cha DR
Kidney Int; 2010 Nov; 78(9):883-94. PubMed ID: 20686445
[TBL] [Abstract][Full Text] [Related]
4. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
5. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice.
Seok SJ; Lee ES; Kim GT; Hyun M; Lee JH; Chen S; Choi R; Kim HM; Lee EY; Chung CH
Nephrol Dial Transplant; 2013 Jul; 28(7):1700-10. PubMed ID: 23794669
[TBL] [Abstract][Full Text] [Related]
6. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
[TBL] [Abstract][Full Text] [Related]
7. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury.
Awad AS; Kinsey GR; Khutsishvili K; Gao T; Bolton WK; Okusa MD
Am J Physiol Renal Physiol; 2011 Dec; 301(6):F1358-66. PubMed ID: 21880831
[TBL] [Abstract][Full Text] [Related]
8. Effects of a CCR2 antagonist on macrophages and Toll-like receptor 9 expression in a mouse model of diabetic nephropathy.
Ito S; Nakashima H; Ishikiriyama T; Nakashima M; Yamagata A; Imakiire T; Kinoshita M; Seki S; Kumagai H; Oshima N
Am J Physiol Renal Physiol; 2021 Dec; 321(6):F757-F770. PubMed ID: 34719947
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy.
Yang SJ; IglayReger HB; Kadouh HC; Bodary PF
Diabetologia; 2009 May; 52(5):972-81. PubMed ID: 19277603
[TBL] [Abstract][Full Text] [Related]
10. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.
Sayyed SG; Ryu M; Kulkarni OP; Schmid H; Lichtnekert J; Grüner S; Green L; Mattei P; Hartmann G; Anders HJ
Kidney Int; 2011 Jul; 80(1):68-78. PubMed ID: 21508925
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in
Tesch GH; Pullen N; Jesson MI; Schlerman FJ; Nikolic-Paterson DJ
Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1439-F1449. PubMed ID: 31566438
[TBL] [Abstract][Full Text] [Related]
12. Critical role of chemokine (C-C motif) receptor 2 (CCR2) in the KKAy + Apoe -/- mouse model of the metabolic syndrome.
Martinez HG; Quinones MP; Jimenez F; Estrada CA; Clark K; Muscogiuri G; Sorice G; Musi N; Reddick RL; Ahuja SS
Diabetologia; 2011 Oct; 54(10):2660-8. PubMed ID: 21779871
[TBL] [Abstract][Full Text] [Related]
13. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.
Chow F; Ozols E; Nikolic-Paterson DJ; Atkins RC; Tesch GH
Kidney Int; 2004 Jan; 65(1):116-28. PubMed ID: 14675042
[TBL] [Abstract][Full Text] [Related]
14. Podocyte-specific knockin of PTEN protects kidney from hyperglycemia.
Wang H; Feng Z; Xie J; Wen F; Jv M; Liang T; Li J; Wang Y; Zuo Y; Li S; Li R; Li Z; Zhang B; Liang X; Liu S; Shi W; Wang W
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1096-F1107. PubMed ID: 29361670
[TBL] [Abstract][Full Text] [Related]
15. The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions.
Nam BY; Paeng J; Kim SH; Lee SH; Kim DH; Kang HY; Li JJ; Kwak SJ; Park JT; Yoo TH; Han SH; Kim DK; Kang SW
Apoptosis; 2012 Jan; 17(1):1-13. PubMed ID: 22006533
[TBL] [Abstract][Full Text] [Related]
16. Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice.
O'Brien PD; Hinder LM; Parlee SD; Hayes JM; Backus C; Zhang H; Ma L; Sakowski SA; Brosius FC; Feldman EL
Diabetes Obes Metab; 2017 Oct; 19(10):1468-1472. PubMed ID: 28332276
[TBL] [Abstract][Full Text] [Related]
17. C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis.
Wilkening A; Krappe J; Mühe AM; Lindenmeyer MT; Eltrich N; Luckow B; Vielhauer V
Nephrol Dial Transplant; 2020 Feb; 35(2):227-239. PubMed ID: 30597038
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CCR2 reduces macrophage influx and development of chronic renal damage in murine renovascular hypertension.
Kashyap S; Warner GM; Hartono SP; Boyilla R; Knudsen BE; Zubair AS; Lien K; Nath KA; Textor SC; Lerman LO; Grande JP
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F372-84. PubMed ID: 26661648
[TBL] [Abstract][Full Text] [Related]
19. CCR2 knockout ameliorates obesity-induced kidney injury through inhibiting oxidative stress and ER stress.
Lee SJ; Kang JS; Kim HM; Lee ES; Lee JH; Chung CH; Lee EY
PLoS One; 2019; 14(9):e0222352. PubMed ID: 31498850
[TBL] [Abstract][Full Text] [Related]
20. CCR2 inhibition: a panacea for diabetic kidney disease?
Weir MR
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):666-7. PubMed ID: 26268909
[No Abstract] [Full Text] [Related]
[Next] [New Search]
